Cargando…

Advances in Hodgkin Lymphoma: Including the Patient’s Voice

Since the initial treatment with radiation therapy in the 1950s, the treatment of Hodgkin lymphoma has continued to evolve, balancing cure and toxicity. This approach has resulted in low rates of relapse and death and fewer short and late toxicities from the treatments used in pursuit of cure. To ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Christine Moore, Friedman, Debra L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914051/
https://www.ncbi.nlm.nih.gov/pubmed/35280764
http://dx.doi.org/10.3389/fonc.2022.855725
_version_ 1784667610633207808
author Smith, Christine Moore
Friedman, Debra L.
author_facet Smith, Christine Moore
Friedman, Debra L.
author_sort Smith, Christine Moore
collection PubMed
description Since the initial treatment with radiation therapy in the 1950s, the treatment of Hodgkin lymphoma has continued to evolve, balancing cure and toxicity. This approach has resulted in low rates of relapse and death and fewer short and late toxicities from the treatments used in pursuit of cure. To achieve this balance, the field has continued to progress into an exciting era where the advent of more targeted therapies such as brentuximab vedotin, immunotherapies such as PD-1 inhibitors, and chimeric antigen receptor T-cells (CAR-T) targeted at CD30 are changing the landscape. As in the past, cooperative group and international collaborations are key to continuing to drive the science forward. Increased focus on patient-reported outcomes can further contribute to the goal of improved outcomes by examining the impact on the individual patient in the acute phase of therapy and on long-term implications for survivors. The goals of this review are to summarize recent and current clinical trials including reduction or elimination of radiation, immunotherapies and biologically-targeted agents, and discuss the use of patient-reported outcomes to help discern directions for new therapeutic regimens and more individualized evaluation of the balance of cure and toxicity.
format Online
Article
Text
id pubmed-8914051
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89140512022-03-12 Advances in Hodgkin Lymphoma: Including the Patient’s Voice Smith, Christine Moore Friedman, Debra L. Front Oncol Oncology Since the initial treatment with radiation therapy in the 1950s, the treatment of Hodgkin lymphoma has continued to evolve, balancing cure and toxicity. This approach has resulted in low rates of relapse and death and fewer short and late toxicities from the treatments used in pursuit of cure. To achieve this balance, the field has continued to progress into an exciting era where the advent of more targeted therapies such as brentuximab vedotin, immunotherapies such as PD-1 inhibitors, and chimeric antigen receptor T-cells (CAR-T) targeted at CD30 are changing the landscape. As in the past, cooperative group and international collaborations are key to continuing to drive the science forward. Increased focus on patient-reported outcomes can further contribute to the goal of improved outcomes by examining the impact on the individual patient in the acute phase of therapy and on long-term implications for survivors. The goals of this review are to summarize recent and current clinical trials including reduction or elimination of radiation, immunotherapies and biologically-targeted agents, and discuss the use of patient-reported outcomes to help discern directions for new therapeutic regimens and more individualized evaluation of the balance of cure and toxicity. Frontiers Media S.A. 2022-02-25 /pmc/articles/PMC8914051/ /pubmed/35280764 http://dx.doi.org/10.3389/fonc.2022.855725 Text en Copyright © 2022 Smith and Friedman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Smith, Christine Moore
Friedman, Debra L.
Advances in Hodgkin Lymphoma: Including the Patient’s Voice
title Advances in Hodgkin Lymphoma: Including the Patient’s Voice
title_full Advances in Hodgkin Lymphoma: Including the Patient’s Voice
title_fullStr Advances in Hodgkin Lymphoma: Including the Patient’s Voice
title_full_unstemmed Advances in Hodgkin Lymphoma: Including the Patient’s Voice
title_short Advances in Hodgkin Lymphoma: Including the Patient’s Voice
title_sort advances in hodgkin lymphoma: including the patient’s voice
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914051/
https://www.ncbi.nlm.nih.gov/pubmed/35280764
http://dx.doi.org/10.3389/fonc.2022.855725
work_keys_str_mv AT smithchristinemoore advancesinhodgkinlymphomaincludingthepatientsvoice
AT friedmandebral advancesinhodgkinlymphomaincludingthepatientsvoice